Cox 2 Inhibitor News and Research

RSS

Cox-2 Inhibitors are nonsteroidal anti-inflammatory drugs used to relieve pain and inflammation. COX-2 inhibitors are being studied in the prevention of colon polyps, and as anticancer drugs. Also called cyclo-oxygenase-2 inhibitor.

Colon cancer patients who took aspirin regularly fared better after surgery

Colon cancer patients who took aspirin regularly fared better after surgery, reducing their risk of disease recurrence and death by half compared to non-users, researchers will report at the annual meeting of the American Society of Clinical Oncology.

16 May 2005

Blocking the COX-1 enzyme might be the answer in ovarian cancer treatment

Researchers at Vanderbilt University Medical Center in a new report say that blocking the COX-1 enzyme - not COX-2 - might lead to a way to prevent and treat the most common and fatal form of ovarian cancer.

2 May 2005

Blocking the COX-1 enzyme might prevent and treat the most common and fatal form of ovarian cancer

Blocking the COX-1 enzyme - not COX-2 - might lead to a way to prevent and treat the most common and fatal form of ovarian cancer, researchers at Vanderbilt University Medical Center reported this week.

1 May 2005

Study predicted cardiovascular risk of Cox-2 inhibitors

Amid the recent controversy and confusion over serious side effects from pain medications, a new UCLA and Veterans Affairs Greater Los Angeles Healthcare System study demonstrates that for arthritis sufferers at high risk for gastrointestinal problems who traditionally may have used a drug like Vioxx, the most cost-effective and safest treatment is actually a common painkiller combined with an acid-reducing drug.

11 Apr 2005

Pfizer separately agrees to suspend sales of Bextra due to FDA evaluation of risks of rare but serious skin reactions

Pfizer said today it will work with the U.S. Food and Drug Administration (FDA) to add expanded risk information in the Celebrex label following an FDA decision announced this morning to require boxed warnings of potential cardiovascular risk for all COX-2 pain relievers and all NSAIDs, including older non-specific drugs such as ibuprofen and naproxen.

7 Apr 2005

Patch therapy provides similar pain relief as oral medications for patients with osteoarthritis (OA) knee pain

Researchers from the Altoona Arthritis and Osteoporosis Center have announced that data presented at the 24th Annual Scientific Meeting of the American Pain Society suggest that patch therapy provides similar pain relief as oral medications for patients with osteoarthritis (OA) knee pain.

3 Apr 2005

International expert group discusses alternatives to COX-2 inhibitors

International group of pain specialists meets to develop recommendations for the treatment of chronic moderate-to-severe pain in the wake of the global withdrawal of rofecoxib (Vioxx) and concerns regarding use of other COX-2 inhibitors.

7 Mar 2005

New research offers natural alternative to arthritis drugs

The research, conducted by The Australian Centre for Complementary Medicine Education and Research (ACCMER), shows that Biolane Green Lipped Mussel Extract has a combination of actions that are not associated with increased risk of blood clotting that has caused recent drug withdrawals and medical warnings. In fact, the product may even help slow the progression of osteoarthritis.

1 Mar 2005

Celebrex provides a two pronged attack against prostate cancer

Celecoxib, a selective COX-2 inhibitor with promising anti-cancer properties, has now been found to attack prostate cancer cells in a second way that differs from Vioxx (rofecoxib), another anti-inflammatory drug that also inhibits COX-2.

1 Mar 2005

Painful surgical adhesions may be preventable by taking the COX-2 inhibitor Celebrex

Adhesions – bands of scar tissue that bind together two internal body surfaces – develop in 55 percent to more than 90 percent of patients undergoing surgery, depending on the type of operation. They are part of normal healing, but when surfaces fuse together that shouldn't, serious pain and complications can result.

26 Jan 2005

Vioxx could have caused 140000 excess cases of coronary heart disease in the USA since 1999

The arthritis drug Vioxx could have caused an estimated 88 000–140 000 excess cases of serious coronary heart disease in the USA since its launch in 1999, concludes a study published online by The Lancet.

24 Jan 2005

Study of patients on COX-2 inhibitors does not show increased cardiovascular risk

An observational study of 6,250 patients enrolled in the Maryland Medicaid program found that COX-2 inhibitors did not increase the risk for cardiovascular events over nonnaproxen NSAIDs in a high-risk population.

24 Jan 2005

Physicians should avoid prescribing Bextra altogether

Physicians should avoid prescribing Bextra altogether, or use it only as a drug of last resort, says a researcher from Wake Forest University Baptist Medical Center and colleagues in an editorial published on-line Jan. 17 in Circulation, a publication of the American Heart Association.

19 Jan 2005

Animal study on vascular effects of COX-2 inhibition

In an article by Egan et al, titled, "Cyclooxygenases, Thromboxane, and Atherosclerosis," published in the Jan 17 issue of Circulation: Journal of the American Heart Association researchers examined some of the molecular mechanisms of drugs affecting prostaglandin and thromboxane production.

17 Jan 2005

Further evidence for the role of cyclooxygenases (COX) in heart-disease risk

In two articles, published in Circulation, researchers from the University of Pennsylvania School of Medicine provide further evidence for the role of cyclooxygenases (COX) in heart-disease risk.

17 Jan 2005

Women need less morphine after hysterectomies with new treatment

Women recovering from hysterectomies require less morphine to combat pain and are able to recover their lung function more quickly when they receive a combination of two non-morphine-like or “non-opioid” drugs as part of their treatment, a new Queen’s study shows.

5 Jan 2005

Arthritis drug caution advised by New Zealand experts

An expert New Zealand committee reviewing the safety of a group of arthritis drugs called COX-2 inhibitors has reinforced UK advice cautioning against their routine use where safe and effective alternatives are available.

21 Dec 2004

New advice on anti-inflammatory drugs called Cox-2 Inhibitors, including Celebrex

Patients who are taking Celebrex, Bextra and Arcoxia should make a non-urgent appointment with their GP to review their treatment. Patients who have established heart disease or who are at high risk of stroke will have their treatment changed.

21 Dec 2004

Advice for patients who have been taking Celebrex or Bextra

The recent announcement that Celebrex, a popular pain drug in the same family as Vioxx, has been found to pose an increased risk of heart problems is bound to leave many pain patients stunned, confused and worried.

20 Dec 2004

Celebrex suspension

The National Institutes of Health (NIH) announced that it has suspended the use of COX-2 inhibitor celecoxib (Celebrex™ Pfizer, Inc.) for all participants in a large colorectal cancer prevention clinical trial conducted by the National Cancer Institute (NCI).

19 Dec 2004